The latest price target for WAVE Life Sciences (NASDAQ:WVE) was reported by JP Morgan on September 9, 2024. The analyst firm set a price target for $10.00 expecting WVE to rise to within 12 months (a possible 80.18% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for WAVE Life Sciences (NASDAQ:WVE) was provided by JP Morgan, and WAVE Life Sciences initiated their overweight rating.

The last upgrade for WAVE Life Sciences Ltd happened on December 19, 2023 when Leerink Partners raised their price target to $12. Leerink Partners previously had a market perform for WAVE Life Sciences Ltd.

There is no last downgrade for WAVE Life Sciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of WAVE Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for WAVE Life Sciences was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest WAVE Life Sciences (WVE) rating was a initiated with a price target of $0.00 to $10.00. The current price WAVE Life Sciences (WVE) is trading at is $5.55, which is within the analyst’s predicted range.